Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 18

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 18
---
 ​ | Current Position at Tvardi                   | ​ |
| Imran Alibhai, Ph.D.        | ​ | ​ | Chief Executive Officer and                  
 Director                                     | ​ | ​ | Chief Executive Officer and Director         | ​ |
| Dan Conn, J.D., M.B.A.      | ​ | ​ | Chief Financial Officer                      | ​ | ​ | Chief Financial Officer                      | ​ |
| John Kauh, M.D.             | ​ | ​ | Chief Medical Officer                        | ​ | ​ | Chief Medical Officer                        | ​ |
| Jeffrey Larson, Ph.D., DABT | ​ | ​ | Senior Vice President, Research &Development | ​ | ​ | Senior Vice President, Research &Development | ​ |
| Yixin “Joseph” Chen, Ph.D.  | ​ | ​ | Vice President, Chemistry,                   
 Manufacturing and Controls                   | ​ | ​ | Vice President, Chemistry,                   
 Manufacturing and Controls                   | ​ |

4

TABLE OF CONTENTS

Q:

As a stockholder of Cara, how does the Cara Board recommend that I vote?

A:

After careful consideration, the Cara Board recommends that the holders of Cara common stock vote:

#### •

“

#### FOR
” Proposal 1 — the Stock Issuance Proposal;

#### •

“

#### FOR
” Proposal 2 — the Equity Plan Proposal;

#### •

“

#### FOR
” Proposal 3 — the ESPP Proposal;

#### •

“

#### FOR
” Proposal 4 — the Reverse Stock Split Proposal;

#### •

“

#### FOR
” Proposal 5 — the Authorized Share Proposal;

#### •

“

#### FOR
” Proposal 6 — the Compensation Proposal; and

#### •

“

#### FOR
” Proposal 7 — the Adjournment Proposal.

For more information on each proposal and the Cara Board’s recommendations, please see the section titled “ Matters Being Submitted to a Vote of Cara’s Stockholders ” beginning on page 217of this proxy statement/prospectus.

**Q:

How many votes are needed to approve each Cara Proposal?

A:

Approval of each of the Stock Issuance Proposal, the Equity Plan Proposal, the ESPP Proposal, the Reverse Stock Split Proposal and the Authorized Share Proposal requires the affirmative vote from a majority of the votes cast by the holders of shares present at the meeting (by virtual attendance) or represented by proxy. Approval of the Compensation Proposal and the Adjournment Proposal requires votes from the majority of shares present in person (by virtual attendance) or